BioSpace News Archive

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced it has completed enrollment of its Phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea.

In our continued efforts to establish long-term partnership with our clients, FDAQRC is expanding in Current Good Manufacturing Practices (cGMP) by including a broad range of comprehensive quality and regulatory compliance services.

Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate in the brain and body of every patient, and carry an FDA “black box” warning about gadolinium, a heavy metal they use to generate contrast.

Amsterdam, the Netherlands – Royal Philips announced that it will repurchase up to 3.2 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchase plans.

Precipio, Inc., announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market share.

Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two presentations were delivered at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany.

The U.S. Food and Drug Administration approved Olumiant oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year.

Treadwell Therapeutics announced the initiation of patient dosing in TWT-203, its Phase 1b/2 study to evaluate CFI-402257, an oral, best-in-class inhibitor of Threonine Tyrosine Kinase in patients with advanced solid tumors and ER+/Her2- breast cancer.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to the company’s Board of Directors, effective June 10, 2022.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Executive Officer, Ivor Royston , M.D., is being presented with the Science History Institute’s Biotechnology Heritage Award.